Dr Reddys enters the Dermatology topical steroid market with the launch of 'UltravexTM' - (Halobetasol)

Dr Reddys Laboratories Ltd has announced that Ultravex™ (Halobetasol) has been launched nationwide in June marking the entry of the Company's Dermatology in the topical steroid Rs 100 crore market. Halobetasol is a super - potent steroid and hence has a higher efficacy associated with the product. Ultravex™ is currently available in 10 gm pack and is used in the treatment of Psoriasis and Chronic Dermatoses.

The topical steroid market is the second most prescribed category by dermatologists with nearly 2.5 crore units sold every year. With the launch of this product, the Company steps into a mass specialty area which has an higher incidence of prescription due to its indication (Psoriasis and Chronic Dermatoses).